 |
|
|
| |
Impact of Susceptibility Scoring on Virologic Response in Heavily Treatment-Experienced
Participants with HIV-1 Receiving a Fostemsavir-Based Antiretroviral Regimen: Week 96 Results from
the Randomized Cohort of the Phase 3 BRIGHTE Study
|
| |
| |
EACS 2019 Nov 6-9 Basel
Reported by Jules Levin
M. Lataillade1, C. Llamoso1, A. Pierce2, M. Gartland2, Mark Krystal1, S. Chabria1, Marcia Wang3, P. Ackerman1
1ViiV Healthcare, Branford, United States, 2ViiV Healthcare, Research Triangle Park, United States, 3GlaxoSmithKline, Upper Providence, United States
|
| |
|
|
|
|
|
